Skip to Main Content

Paper Details

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Clin Cancer Res
8
2020
Alisertib, Aurora A Kinase, Aurora A kinase, Solid Tumors, TAK, TAK-228, TNBC, TNBC PDX models, TNBC cell, TNBC cell lines, TORC1/2, advanced solid tumors, alisertib, alopecia, fatigue, mTOR, mucositis, nausea, neutropenia, patient, patient-derived xenograft (PDX) models, patients, rash, solid tumors, triple-negative breast cancer
Author NameAffiliation
Aik Choon TanMoffitt Cancer Center
Aik Choon TanMoffitt Cancer Center
Wells A MessersmithUniversity of Colorado Cancer Center
  • 1 - 3

Datasets

Release 1.2